TCT 2019

TCT 2019


September 25 – 29 | Booth #1739

Moscone Center, San Francisco

Join us at TCT 2019 to experience our most advanced, integrated product solutions yet. Philips uniquely integrates best-in-class physiology, imaging and co-registration into our systems and specialized diagnostic and therapeutic devices. We help you see clearly and treat optimally in interventional procedures, because there is always a way to make life better.

Visit our booth #1739 or register to attend one our educational events.

Join us at these TCT events

Breakfast Symposium

New frontiers in PCI: ultra-low contrast, artificial Intelligence and co-registration

Educate physicians in the use of various technologies including physiology, co-registration and imaging techniques to optimize outcomes. Question and answer session with the expert panel to further participant’s knowledge and understanding.

Friday, September 27, 2019
6:30 – 8:00 AM
Room 213, Level 2, Moscone South

Moderator: Dr. Jasvindar Singh, Barnes-Jewish
Speakers: Dr. Jasvindar Singh, Dr. Allen Jeremias, Dr. Javier Escaned

Philips Training Pavilion

Learn and discuss with experts how Philips’ specialty coronary diagnostic and therapy devices help you see clearly and treat optimally. Attend one of the expert-led training sessions by registering online or visiting Pavilion 1 – North Hall.

Friday, September 27, 2019
CRF Pavilion 1 – North Hall
8:00 – 9:30 AM, 10:00 – 11:30 AM, 12:00 – 1:30 PM, 2:00 – 3:30 PM, 4:00 – 5:30 PM

Philips NDA Rooms

Get hands-on experience with the cath lab of the future and the newest Philips technologies. Please be prepared to sign a non-disclosure agreement.

Booth #1739
Open during booth hours

Philips laser training

Pre-register for the Philips ELCA laser atherectomy hands-on workshop to learn from global thought leaders about the clinical applications of laser technology for coronary atherectomy procedures.
intrasight product video
The Philips IntraSight applications platform is where imaging, physiology, co-registration* and software all come together to clearly identify coronary and peripheral artery disease, helping you provide more optimized treatment plans. Philips IntraSight seamlessly integrates with Azurion for interventional excellence.

Featured technologies:

Image guided therapy devices:

iFR modality

iFR is the gold standard among resting indices backed by data from more than 4500 patients across two large trials. Use of iFR reduces costs, procedural time and patient discomfort 1,2,3 while providing advanced guidance with co-registration. 

ELCA laser atherectomy catheter

Designed to cross, prepare and treat the most complex coronary lesions by de-bulking and modifying plaque of multiple morphologies. ELCA is used for atherectomy in a broad range of coronary indications.

Visions PV digital IVUS catheters

Angiography is not enough. IVUS may help to determine pathology at the ambiguous site to optimize your treatment strategy and device utilization.

iFR Co-registration 

Decide not just whether to treat, but where to treat by mapping iFR values directly onto the angiogram to see precisely which parts of a vessel are causing ischemia, as well as the physiologic impact of your treatment strategy with virtual stenting.

Turbo-Power and Turbo-Elite laser atherectomy catheters

Achieve your patient specific treatment goals with  safe, effective and proven solutions that can be used in mixed morphologies across a variety of vessel sizes and may be used in conjunction with IVUS. Turbo-Power is approved for use in in-stent restenosis cases.

Image guided therapy systems:


Philips Azurion is the next-generation image guided therapy platform that allows you to easily and confidently perform procedures, helping you optimize your lab performance and provide superior care. Azurion has been developed in close collaboration with our clinical partners to ensure workflow solutions that meet the continuing demands of the interventional lab.

Dynamic Coronary Roadmap

Dynamic Coronary Roadmap, a Philips-exclusive technology, creates a motion-compensated, real-time view of coronary arteries. A highlighted coronary angiogram is superimposed on a live 2D fluoroscopic image, creating a colored roadmap that adjusts automatically, providing continuous visual feedback on positioning of wires and catheters.

Azurion with FlexArm

The latest addition to the Azurion family, Azurion with FlexArm is a revolutionary new interventional suite that provides unlimited imaging flexibility for diverse procedures and exceptional positioning freedom for medical teams.  With the full flexibility and compact set-up of the FlexArm stand you have a highly cost-effective environment ready for the procedures of the future.

Cardiovascular Ultrasound:

Cardiovascular Ultrasound

In today's cardiology environment, there is pressure to implement imaging solutions that are cutting-edge, without compromising workflow efficiencies, diagnosis and treatment, or patient care.  Philips cardiovascular ultrasound systems bring outstanding functionality and performance that help you to improve quality of care and workflow within the cardiology department and cath labs supporting structural heart procedures – allowing you to deliver superb care to each and every patient.

EPIQ CVxi and EchoNavigator with Anatomical Intelligence

The dedicated EPIQ CVxi for the cath lab with the new integrated EchoNavigatorA.I., gives you control of live fusion imaging directly from the system, streamlining communication between the echocardiographer and the interventional cardiologist. EchoNavigator automatically fuses live 3D TEE and live X-ray in real time so you can intuitively guide your device in the 3D space more quickly.

What's trending

* Co-registration tools available within IntraSight 7 configuration via SyncVision.

1. Davies JE, et al., Use of the Instantaneous Wave-free Ratio or Fractional Flow Reserve in PCI. N Engl J Med. 2017 May 11;376(19):1824-1834.
2. Gotberg M, et al., iFR-SWEDEHEART Investigators.. Instantaneous Wave-free Ratio versus Fractional Flow Reserve to Guide PCI. N Engl J Med. 2017 May 11;376(19):1813-18233.
3. Patel M. “Cost-effectiveness of instantaneous wave-Free Ratio (iFR) compared with Fractional Flow Reserve (FFR) to guide coronary revascularization decision making.” Late-breaking Clinical Trial presentation at ACC on March 10, 2018.

ELCA important safety information
The laser catheters are intended for use either as a stand-alone modality or in conjunction with percutaneous transluminal coronary balloon angioplasty (PTCA) in patients who are acceptable candidates for coronary artery bypass graft (CABG) surgery. The following indications for use, contraindications and warnings have been established through multicenter clinical trials. The Philips CVX-300 Excimer laser system and the multi-fiber laser catheter models are safe and effective for the following indications: occluded saphenous vein bypass grafts, ostial lesions, long lesions (greater than 20mm in length), moderately calcified stenosis, total occlusions traversable by a guidewire, lesions which previously failed balloon angioplasty, restenosis in 316L stainless steel stents, prior to the administration of intravascular brachytherapy. These lesions must be traversable by a guidewire and composed of atherosclerotic plaque and/or calcified material. The lesions should be well defined by angiography.
Contraindications: Lesion is in an unprotected left main artery. Lesion is beyond acute bends or is in a location within the coronary anatomy where the catheter cannot traverse. Guidewire cannot be passed through the lesion. Lesion is located within a bifurcation. Patient is not an acceptable candidate for bypass graft surgery.
Potential adverse events: Use of the Philips CVX-300 Excimer laser system may contribute to the following complications: dissection of the arterial wall, perforation, acute reclosure, embolization, aneurysm formation, spasm, coronary artery bypass graft surgery, thrombus, myocardial infarction, arrhythmia, filling defects, death. No long term adverse effects of ELCA are known at this time.
Risks: The primary endpoint defined in the laser angioplasty of restenosis stents (LARS) randomized trial was the absence of major adverse cardiac events (MACE) at 6 months: Death; myocardial infarction; coronary artery bypass surgery. Procedural complications include: any dissection, acute thrombus, haziness, no reflow, arrhythmia, acute vessel closure, occlusion of side branch, occlusion non-target, coronary spasm, coronary embolism, coronary perforation, laser/stent damage, balloon/stent damage, and other serious.
Caution: Federal law restricts this device to sale by or on the order of a physician.